Theradaptive任命Daniel Wolf为首席财务官，继续执行管理层转型-动脉网

Theradaptive Appoints Daniel Wolf as Chief Financial Officer, Continuing Executive Transformation

CISION 等信源发布 2025-04-22 21:35



可切换为仅中文







FREDERICK, Md.

马里兰州弗雷德里克

，

April 22, 2025

2025年4月22日

/PRNewswire/ -- Theradaptive, a clinical-stage biotechnology company pioneering targeted protein therapeutics for tissue regeneration, is pleased to announce the appointment of

/PRNewswire/ -- Theradaptive，一家处于临床阶段的生物技术公司，致力于开发用于组织再生的靶向蛋白质治疗药物，欣然宣布任命

Daniel Wolf

丹尼尔·沃尔夫

as Chief Financial Officer (CFO). Wolf brings more than two decades of leadership experience in the medical device and healthcare sectors, including senior roles at Medtronic and Baxter International.

作为首席财务官（CFO）。沃尔夫在医疗设备和医疗保健领域拥有二十多年的领导经验，包括在美敦力和百特国际担任高级职务。

Wolf most recently served as Senior Vice President, Chief Strategy and M&A Officer at Baxter International. Prior to Baxter, he spent over 12 years at Medtronic, where he held a variety of leadership positions predominantly in the Spine & Biologics division, including President of Medicrea and Vice President and General Manager of Intelligent Data Solutions.

沃尔夫最近担任百特国际高级副总裁、首席战略官和并购官。在加入百特之前，他在美敦力工作了12年以上，期间主要在脊柱和生物制品部门担任过多种领导职务，包括Medicrea总裁以及智能数据解决方案副总裁兼总经理。

During his tenure at Medtronic, Wolf led major strategic transactions and played a key role in business development, corporate strategy, and healthcare economics..

在美敦力任职期间，沃尔夫领导了多项重大战略交易，并在业务发展、企业战略和医疗经济方面发挥了关键作用。

Wolf holds a Bachelor of Arts in Economics from

沃尔夫持有经济学学士学位，毕业于

Bowdoin College

鲍登学院

, a Master of Business Administration from

，工商管理硕士来自

Harvard Business School

哈佛商学院

, and a Master of Science in Health Sciences and Technology from the

，以及健康科学与技术理学硕士来自

Massachusetts Institute of Technology

麻省理工学院

. He currently serves as a board director for SI-Bone.

他目前担任SI-Bone的董事会董事。

'We are delighted to welcome Dan to the Theradaptive team,' said Dr.

“我们非常高兴欢迎丹加入Theradaptive团队，”博士说道。

Luis M. Alvarez

路易斯·M·阿尔瓦雷斯

, Founder and CEO of Theradaptive. 'Dan's proven track record in financial leadership, strategic growth, and M&A in our specific field of interest will be instrumental as we accelerate towards commercialization of our targeted therapeutic delivery platform. Dan is uniquely prepared to manage the rapidly growing interest among strategics and large investors heading into our Series B this summer.'.

Theradaptive的创始人兼首席执行官表示：“Dan在我们感兴趣的特定领域的财务领导、战略增长和并购方面有着良好的记录，这将在我们加速推进靶向治疗递送平台的商业化过程中发挥关键作用。Dan有充分的准备管理战略方和大型投资者对我们日益增长的兴趣，并顺利进入今年夏季的B轮融资。”

Wolf's appointment as CFO is part of a broader executive transformation that started with the appointment of Dr. Frank Vizesi as CSO, and continued with the addition of

沃尔夫被任命为首席财务官是更广泛的行政转型的一部分，这一转型始于弗兰克·维泽西博士被任命为首席战略官，并随着增添新人而继续进行。

Jeffrey Dunn

杰弗里·邓恩

to the Board of Directors. All three are seasoned medical device executives that bring a wealth of experience in spine and musculoskeletal in preparation for the highest value creation period in the company's history.

向董事会任职。这三位都是一流的医疗器械主管，在脊柱和骨骼肌肉方面拥有丰富的经验，为公司历史上价值创造最高的时期做好准备。

Wolf commented, 'Theradaptive's innovative approach to targeted therapeutic delivery is a gamechanger and its commitment to transforming patient care is truly inspiring. I look forward to working with the team to drive the company's next phase of growth and deliver value to patients, partners, and investors.'.

沃尔夫评论道：“Theradaptive公司针对目标治疗传输的创新方法是一种颠覆性的变革，其致力于转变患者护理的承诺真的鼓舞人心。我期待与团队合作，推动公司下一阶段的增长，并为患者、合作伙伴和投资者带来价值。”

'Dan is a world-class leader with deep experience across strategy, finance, and M&A in the musculoskeletal space,' said

“丹是一位世界级的领导者，在肌肉骨骼领域的战略、财务和并购方面拥有深厚的经验，”

Jeffrey Dunn

杰弗里·邓恩

, Member of the Board. 'His leadership will be critical as the company continues to grow and engage with key stakeholders across the industry.'

，董事会成员。“随着公司继续发展并与行业内的关键利益相关者接触，他的领导将至关重要。”

Founded in 2017 and headquartered in

成立于2017年，总部位于

Frederick, Maryland

马里兰州弗雷德里克

, Theradaptive is at the forefront of developing novel protein engineering technologies that enable precise therapeutic delivery for multiple indications. The appointment of

，Theradaptive处于开发新型蛋白质工程技的前沿，该技术能够实现针对多种适应症的精准治疗递送。

Daniel Wolf

丹尼尔·沃尔夫

as CFO underscores Theradaptive's commitment to deepening its executive team as it enters a period of exceptional value creation that will follow completion of enrollment in its Phase II study.

作为首席财务官，强调了Theradaptive在进入二期研究完成后的特殊价值创造时期，致力于深化其执行团队的承诺。

About Theradaptive

关于Theradaptive

Theradaptive

is a privately held, clinical-stage biologics company developing protein therapeutics for spine, orthopedics, dental, and soft tissue repair and targeted therapeutics in diverse areas such as immuno-oncology. The company leverages its therapeutic delivery platform to deliver recombinant biologics to targeted areas in the body with high precision and persistence to address unmet medical needs.

是一家私人持有的临床阶段生物制品公司，致力于开发用于脊柱、骨科、牙科和软组织修复的蛋白质疗法，以及针对免疫肿瘤学等多样化领域的靶向治疗药物。该公司利用其治疗递送平台，将重组生物制品以高精度和持久性递送到人体特定部位，以满足尚未解决的医疗需求。

For more information on Theradaptive and its clinical development program, visit .

如需更多关于Theradaptive及其临床开发计划的信息，请访问。

www.theradaptive.com

and follow the company on

并关注公司

领英

。

OsteoAdapt

骨适应

™

SP is an Investigational Device. Limited by US Federal law to investigational use.